A specialized integrin-binding motif enables proTGF-β2 activation by integrin αVβ6 but not αVβ8. 2023

Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
Program in Cellular and Molecular Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115.

Activation of latent transforming growth factor (TGF)-β2 is incompletely understood. Unlike TGF-β1 and β3, the TGF-β2 prodomain lacks a seven-residue RGDLXX (L/I) integrin-recognition motif and is thought not to be activated by integrins. Here, we report the surprising finding that TGF-β2 contains a related but divergent 13-residue integrin-recognition motif (YTSGDQKTIKSTR) that specializes it for activation by integrin αVβ6 but not αVβ8. Both classes of motifs compete for the same binding site in αVβ6. Multiple changes in the longer motif underlie its specificity. ProTGF-β2 structures define interesting differences from proTGF-β1 and the structural context for activation by αVβ6. Some integrin-independent activation is also seen for proTGF-β2 and even more so for proTGF-β3. Our findings have important implications for therapeutics to αVβ6 in clinical trials for fibrosis, in which inhibition of TGF-β2 activation has not been anticipated.

UI MeSH Term Description Entries
D005355 Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. Cirrhosis,Fibroses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D016023 Integrins A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors (RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation. Integrin
D016212 Transforming Growth Factor beta A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. Bone-Derived Transforming Growth Factor,Platelet Transforming Growth Factor,TGF-beta,Milk Growth Factor,TGFbeta,Bone Derived Transforming Growth Factor,Factor, Milk Growth,Growth Factor, Milk
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP
D053781 Transforming Growth Factor beta2 A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. TGF-beta2,BSC-1 Cell Growth Inhibitor,Cartilage-Inducing Factor-B,Glioblastoma-Derived T-Cell Suppressor Factor,Polyergin,Suppressor Factor, T-Cell, Glioblastoma-Derived,TGF-beta-2,TGF-beta2 Latency-Associated Protein,TGF-beta2LAP,Transforming Growth Factor beta 2 Latency Associated Peptide,BSC 1 Cell Growth Inhibitor,Cartilage Inducing Factor B,Glioblastoma Derived T Cell Suppressor Factor,Latency-Associated Protein, TGF-beta2,TGF beta2 Latency Associated Protein,TGF beta2LAP

Related Publications

Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
July 2015, Proceedings of the National Academy of Sciences of the United States of America,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
October 2021, EJNMMI research,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
April 2022, Bio-protocol,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
April 2020, Nanoscale,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
May 2016, The Journal of biological chemistry,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
May 2021, Journal of medicinal chemistry,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
November 2018, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
December 2011, Journal of virology,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
December 2021, PLoS pathogens,
Viet Q Le, and Bo Zhao, and Siddanth Ramesh, and Cameron Toohey, and Adam DeCosta, and Julian Mintseris, and Xinyue Liu, and Steven Gygi, and Timothy A Springer
April 2022, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
Copied contents to your clipboard!